Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2023-10-19 Earnings Release
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Inside Information / Information on annual revenues
Earnings Release Classification · 98% confidence The document is titled "Mauna Kea Technologies Reports 74% Increase in 9-Month 2023 Sales" and provides detailed financial highlights, tables comparing Q3 2023 vs Q3 2022, and 9M 2023 vs 9M 2022 revenue figures, along with commentary from the CEO. This structure is characteristic of an initial announcement of periodic financial results, focusing on key figures rather than the comprehensive detail found in a full Annual Report (10-K) or Interim Report (IR). Since it explicitly reports on the third quarter and nine months ended September 30, 2023, and is presented as a press release announcing these results, it fits the definition of an Earnings Release (ER). It is not a transcript (CT), a full audit report (AR), or a presentation (IP). 9M 2023
2023-10-19 English
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 98% confidence The document is titled with a headline announcing revenue growth for the first 9 months of 2023 and provides detailed financial highlights for the third quarter (T3 2023) and the nine-month period ending September 30, 2023. It includes comparative tables showing revenue breakdown by segment and geography, along with management commentary. This structure is characteristic of an Earnings Release (ER), which is the initial announcement of periodical financial results, focusing on key highlights and summary figures, rather than a comprehensive, audited report (10-K or IR). Since it explicitly announces the results for the 9-month period and the 3rd quarter, 'ER' is the most appropriate classification. 9M 2023
2023-10-19 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 93% confidence The document is a press release dated October 17, 2023, announcing the publication of positive results from a randomized controlled trial regarding the use of Cellvizio in diagnosing Interstitial Lung Diseases (ILD). It details clinical findings, quotes the CEO, and includes standard sections like 'About Mauna Kea Technologies' and 'Investor Relations'. This format strongly suggests an initial announcement of financial or operational news, often accompanying or preceding a more detailed report. Since it focuses on announcing results and operational progress rather than being a comprehensive annual report (10-K), a quarterly report (IR), or a formal transcript (CT), it fits best as an Earnings Release (ER) if the results are financial, or a general Regulatory Filing (RNS) if the focus is purely operational/clinical. Given the context of announcing 'résultats positifs' (positive results) and the structure typical of an earnings-related announcement, ER is a strong candidate. However, since the results are specifically about a clinical trial publication in a medical journal ('Respiration'), and not explicitly tied to a standard quarterly earnings period, it functions as a significant operational update. In the absence of explicit quarterly financial figures, and given that it is a formal announcement of a major development, it aligns closely with the scope of an Earnings Release (ER) which often includes key operational highlights, or potentially a Regulatory Filing (RNS) if it's a mandatory disclosure. Since it announces 'résultats positifs' which often drives investor sentiment similar to an ER, I will classify it as ER, as it is a primary announcement of performance indicators, even if clinical rather than purely financial. It is not a Report Publication Announcement (RPA) because it contains the substance of the news, not just a notice that a report is available.
2023-10-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 99% confidence The document is titled "Mauna Kea Technologies Announces the Publication of Positive Results of a Randomized Controlled Trial..." and details the results of a clinical study published in a peer-reviewed journal. It is a press release format, announcing a specific piece of information (publication of trial results) rather than being the full financial report (10-K, IR) or a transcript (CT). Since it is an announcement about the release/publication of specific, non-financial, scientific/operational information, it fits best under the general Regulatory Filings (RNS) category, as it is a formal announcement to the market about a significant operational development, although it is not a standard financial filing. It is not an Earnings Release (ER) as it discusses clinical trial data, not financial performance highlights. Given the options, RNS serves as the best general regulatory/corporate announcement category for non-standard filings like this scientific publication announcement.
2023-10-17 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Monthly information regarding the total number of voting rights and shares comprising the share capital' and provides a table detailing the number of shares and voting rights as of September 30, 2023. This type of regular disclosure concerning the total capital structure and voting rights is a specific regulatory requirement, often related to changes in major shareholdings or capital structure transparency. While it touches upon share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS). It is a specific monthly update on voting rights. Among the provided codes, 'Major Shareholding Notification' (MRQ) is the closest fit as it deals with changes in ownership structure and voting rights thresholds, although MRQ typically refers to crossing specific thresholds. However, given the explicit focus on 'total number of voting rights' and the reference to AMF regulations concerning voting rights calculations, this filing is best categorized as a disclosure related to significant ownership structure information. If a more specific 'Voting Rights Disclosure' code existed, it would be preferred. Since MRQ covers notifications of changes in significant share ownership levels, and this document provides the baseline for those calculations monthly, it is the most appropriate fit among the options, or alternatively, RNS if it's considered a general regulatory filing. Given the specific nature of the content (voting rights count), MRQ is selected over the general RNS fallback.
2023-10-10 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social" (Information relative to the total number of voting rights and shares comprising the share capital). It explicitly references Article L233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF). The core content is a table detailing the number of shares and gross/net voting rights as of September 30, 2023. This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement in France, often related to capital structure changes or general transparency, but it does not fit perfectly into the standard US SEC categories (10-K, ER, etc.). Given the options, this is a specific regulatory announcement concerning share capital and voting rights. While it relates to capital structure, it is primarily a mandatory disclosure of voting rights count. Since it is a specific regulatory disclosure that doesn't match the other specific categories (like DIV, SHA, or DIRS), the most appropriate general regulatory category is 'Regulatory Filings' (RNS), as it is a formal, periodic regulatory update required by the AMF, or potentially 'Share Issue/Capital Change' (SHA) if interpreted broadly, but RNS is safer for specific, non-standard regulatory notices. However, looking closely at the definitions, 'SHA' is for 'New share issues, stock splits, or other capital changes.' This document reports the *current* total, which is often published alongside or following such changes, or simply as a mandatory periodic update. Given the focus on 'droits de vote' (voting rights) and share count, it is a specific regulatory disclosure. Since there is no dedicated 'Voting Rights Disclosure' code, and it is not a general 'Share Issue' (SHA), 'RNS' (Regulatory Filings) serves as the best fit for a specific, non-standard regulatory notice required by the AMF.
2023-10-10 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.